Redeye comments on BioInvent’s first quarter in 2025.
Redeye shares its initial take on Physitrack’s Q1 2025 results.
Redeye provides a brief comment on the latest expansion of the Digital Extremes development agreemen...
Redeye reiterates its base case following the company’s Q1 report.
Visserligen föll Aixias nettoomsättning till 85,9 (205,6) mkr, men fjolårssiffran innehåller jätteor...
'25e-'27e adj. EBITA down 3% Already strong gross margin in Q1 can turn even stronger in H2 ~9x '25e...
Sales -7% (EEs -9%, SCs +15%), EBIT -19% vs. our estimates Opex in line, low equipment sales only a ...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 29 april 2025 att Bolaget har ingått ett ex...
Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phas...
Gapwaves reported a robust quarter, with net sales up 46% y/y, meeting consensus but falling 9% shor...
Egetis delivered sales along expectations and more importantly, the German launch is underway follow...
Redeye provides an update following SSH's Q1 2025 were sales increased by 8% y/y to EUR5.
Redeye updates its view on M.O.B.A. Network following the Q1 2025 report.
Redeye provides an update of its estimates and valuation for Serstech following the Q1 2025 report a...
Redeye updates its estimates and valuation following MedCap releasing its Q1 2025 report.
Taaleri's Q1 headline figures missed our and LSEG consensus' estimates, but the miss can be explaine...
Order momentum from Q4 continues, up 18% y-o-y, de-risking '25e Stronger margin in both segments, bu...
Strong Q1 with operational leverage driving margin expansion Adj.
Acceleration across segments - organic momentum improved Another (self-funded) Thebalux-size acquisi...
Report out 6 May Q1e: sales SEK 39m, +2% y-o-y, EBIT SEK 0.
